Bristol Myers Squibb Company $BMY Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 212,722 shares of the biopharmaceutical company’s stock after selling 8,925 shares during the quarter. Yousif Capital Management LLC’s holdings in Bristol Myers Squibb were worth $11,534,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Kentucky Trust Co boosted its holdings in Bristol Myers Squibb by 20.8% in the fourth quarter. Kentucky Trust Co now owns 10,242 shares of the biopharmaceutical company’s stock valued at $552,000 after purchasing an additional 1,767 shares in the last quarter. Clayton Financial Group LLC boosted its holdings in Bristol Myers Squibb by 9.1% in the fourth quarter. Clayton Financial Group LLC now owns 5,343 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 447 shares in the last quarter. Cane Capital Partners LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $526,000. Steadtrust LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $633,000. Finally, Winthrop Advisory Group LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $242,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BMY shares. Cantor Fitzgerald upped their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday. UBS Group reaffirmed a “buy” rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, March 6th. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Finally, Barclays assumed coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $61.35.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $59.20 on Thursday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The stock has a 50 day moving average of $59.60 and a two-hundred day moving average of $52.98. The stock has a market cap of $120.86 billion, a P/E ratio of 17.16, a P/E/G ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the prior year, the firm posted $1.67 EPS. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.